본문 바로가기

Lesion-Based Evaluation Predicts Treatment Response to Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Korean Multicenter Retrospective Study

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
THYROID29(12) · pp.1811 · 2019
피인용
Web of Science 20Scopus 20
FWCI (Scopus)
1.24
JCR IF
JCR 2018 7.786
ISSN
1050-7256

저자

  1. Lee, Eun Kyung제1저자Center for Thyroid Cancer, National Cancer Center, Goyang, Korea
  2. Kim, Seok-MoDepartment of Surgery, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
  3. 김보현Department of Internal Medicine, Pusan National University Hospital, Biomedical Research Institute, Pusan National University School of Medicine, Busan, Korea
  4. Kim, Min JooDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
  5. Lim, Dong-JunDepartment of Internal Medicine, Seoul St. Mary’s Hospital, Catholic University of Korea, Seoul, Korea
  6. Kim, Min-HeeDepartment of Internal Medicine, Seoul St. Mary’s Hospital, Catholic University of Korea, Seoul, Korea
  7. Shin, Dong YeobDepartment of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
  8. Kang, Ho-CheolDepartment of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea
  9. Ahn, Byeong-CheolDepartment of Nuclear Medicine, School Medicine, Kyungpook National University, Daegu, Korea
  10. Kim, Sun WookDepartment of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  11. Ahn, Hwa YoungDepartment of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea
  12. Park, Young Joo교신저자Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

초록

Background: Lenvatinib, a tyrosine kinase inhibitor (TKI) recently approved for treating radioactive iodine-refractory differentiated thyroid cancer, has been shown to delay disease progression and provide meaningful benefit for overall survival (OS). However, there is no predictive marker for response to lenvatinib before initiating treatment. We comprehensively analyzed clinical and radiological parameters to predict response to lenvatinib using lesion-based assessments. Methods: Medical records were collected from 67 patients treated with lenvatinib in 11 referral hospitals across Korea from June 2015 to December 2017. Up to 96 measurable lesions, defined as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, were evaluated serially until progressive disease (PD) occurred, and tumor doubling time (TDT) was calculated based on changes between historical computed tomography (CT) scans and baseline CT scans performed at treatment initiation. Results: Excluding patients with anaplastic thyroid cancer, no thyroidectomy, nontarget lesions only, or treatment periods of <1 month, 57 patients were analyzed, of whom 7 (12.2%) were TKI-naive. The median progression-free survival was 5.1 months (95% confidence interval [CI], 4.4-9.5), the median OS was 19.3 months (95% CI 12.4-not reached), the mean duration of response was 6.0 +/- 4.4 months, and the objective response rate was 38%. In lesion-based assessments, 31 lesions (32.2%) with significant tumor shrinkage (complete remission or partial response) were significantly associated with shorter TDT (p = 0.02). Patients with rapidly PD with a shorter initial TDT (<6 months) were more likely to respond to lenvatinib (p = 0.03). Patients exposed to lenvatinib at an average of >= 16 mg per day, or who were TKI-naive before treatment with lenvatinib, had a lower risk of progression; however, the risk reduction did not reach statistical significance (daily dosage p = 0.07, TKI exposure p = 0.09). Conclusions: TDT calculations at the beginning of treatment and lesion-based tumor assessment may help identify potential responders to lenvatinib therapy and predict therapeutic responses.

키워드

lenvatinibthyroid cancerKoreaprogressive diseaselesion-based evaluationDOUBLING TIMEMANAGEMENTTHERAPY

식별자

Scopus EID
2-s2.0-85077016982
WoS UID
000495076100001